<DOC>
	<DOC>NCT00720434</DOC>
	<brief_summary>The purpose of this study is to further assess the potency of PF-00868554, an HCV polymerase inhibitor, in subjects chronically infected with HCV by evaluating the antiviral activity of PF-00868554 in combination with current standard of care therapy, pegylated interferon-alpha2a (PEGASYS) and ribavirin (COPEGUS).</brief_summary>
	<brief_title>A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Treatment naive (no prior treatment with IFNa +/ RBV regimens. Subjects who have discontinued IFNa containing regimens after &lt;2 weeks of therapy due to tolerability issues are considered treatment naive. HCV RNA &gt; 100,000 IU/mL at screening. Genotype 1. A diagnosis of chronic HCV infection for at least 6 months. Evidence of acute or chronic infection with HIV or HBV. Exposure within the previous three months to an investigational antiHCV agent. Evidence of severe or decompensated liver disease. Subjects with liver disease unrelated to HCV infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>